TG Therapeutics Inc at B Riley Fall Growth Biotech Best Ideas Series (Virtual) Transcript
Good afternoon, and good morning to folks on the West side of the country. Apologies for the slight delay here in starting up. So we are welcoming you to our fall 2021 Best Idea Series, the fifth chapter. This is Mayank Mamtani, senior biotech analyst representing the broader health care research efforts in bringing to you all our top ideas within this mid-cap therapeutics space that we think remain attractive despite an otherwise duct tape in biotech, although there is some life in the recent days and weeks.
So with that presenting, our next idea TG Therapeutics, ticket TGTX, where I'm pleased to have with me Mike Weiss, Chairman, President and CEO. Thanks so much, Mike, for joining us. But before we get started, I need to make the following quick disclosures. In the normal course of business, B. Riley Securities seek to perform investment banking and other services for companies under coverage and to receive compensation in connection for such said services. In addition, B. Riley makes a market for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |